Aarti Drugs Limited

BSE: AARTIDRUGS524348ISIN INE767A01016

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹454.45-11.15 (-2.39%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹533.60
52W low: ₹318.60
Off 52W high: -14.83%
1M return: +9.45%
3M return: +10.26%
6M return: +14.10%
1Y return: -9.74%
20D avg volume: 39,361
50 DMA: ₹421.44
200 DMA: ₹390.04

Key ratios Consolidated

Market cap: ₹4,148 Cr
Current price: ₹454.45
52W high / low: ₹533.60 / ₹318.60
Face value: ₹10.00
P/E: 18.14
P/B: 2.47
EPS (TTM): ₹25.06
Book value / share: ₹184.24
ROE: —
ROCE: 12.90%
Operating margin: —
Net margin: —
Debt / equity: 0.37
Net debt: ₹567.56 Cr
Interest cover: 7.26
Dividend yield: 0.44%
Dividend / share (TTM): ₹2.00
Payout: 7.98%
Cash conversion cycle: 119.9 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	826.24	702.78	720.30	601.71	652.79	590.51	676.76	556.60	598.33	590.51	619.99	605.94
	2.55	0.81	0.76	1.23	0.09	0.31	1.87	11.90	1.48	0.31	1.08	1.67
	828.79	703.59	721.06	602.94	652.88	590.82	678.63	568.50	599.81	590.82	621.07	607.61
	719.51	632.26	650.70	573.92	592.47	539.71	607.48	517.74	553.93	539.71	556.89	556.06
	477.33	469.35	427.19	334.52	385.06	357.25	375.14	369.79	345.58	357.25	366.64	401.07
	33.13	21.38	33.32	22.51	30.64	28.61	23.13	14.11	29.57	28.61	20.33	21.70
	37.13	36.51	32.28	33.16	33.07	30.80	31.35	27.76	26.56	30.80	25.87	25.55
	9.63	9.22	8.16	9.29	7.70	8.56	9.16	9.07	8.93	8.56	9.13	7.60
	19.00	18.46	18.04	17.95	16.26	14.72	14.88	13.80	13.72	14.72	13.58	12.66
	154.70	140.47	141.80	126.88	127.15	112.24	115.18	115.72	110.72	112.24	111.21	105.02
	109.28	71.33	70.36	29.02	60.41	51.11	71.15	50.76	45.88	51.11	64.18	51.55
	0.00	-2.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	109.28	69.24	70.36	29.02	60.41	51.11	71.15	50.76	45.88	51.11	64.18	51.55
	26.51	19.11	15.10	-11.53	15.25	2.86	8.38	13.67	10.92	-2.86	16.87	14.84
	82.77	50.13	55.26	40.55	45.16	53.97	62.77	37.09	34.96	53.97	47.31	36.71
	9.07	5.49	6.05	4.44	4.95	5.91	6.88	4.06	3.83	5.91	5.15	3.99
Key metrics
	137.91	96.92	96.56	56.26	84.37	74.39	95.19	73.63	68.53	74.39	86.89	71.81
	16.70%	13.80%	13.40%	9.40%	12.90%	12.60%	14.10%	13.20%	11.50%	12.60%	14.00%	11.90%
	10.00%	7.10%	7.70%	6.70%	6.90%	9.10%	9.30%	6.70%	5.80%	9.10%	7.60%	6.10%
	5.90%	—	4.10%	—	3.70%	—	4.60%	—	—	—	—	—
	26.60%	19.00%	6.40%	8.10%	9.10%	0.00%	9.20%	-8.10%	—	—	—	—
	83.30%	-7.10%	-12.00%	9.30%	29.20%	0.00%	32.70%	1.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	2,851	2,565	2,387	2,529	2,716	2,489
	5.35	2.39	16.36	4.03	2.19	11.32
	2,856	2,568	2,403	2,533	2,718	2,500
	2,576	2,357	2,192	2,297	2,494	2,230
	1,708	1,504	1,438	1,572	1,769	1,666
	110.34	115.08	84.34	80.23	121.29	108.57
	139.08	129.32	112.10	102.34	92.02	82.81
	36.30	33.71	35.87	33.52	33.29	20.75
	73.45	66.97	55.78	51.45	50.32	50.05
	563.85	508.08	445.77	432.05	429.92	387.55
	279.99	210.90	211.77	235.53	224.18	269.96
	-2.09	0.00	0.00	0.00	0.00	0.00
	277.90	210.90	211.77	235.53	224.18	269.96
	49.19	15.96	43.67	63.94	57.82	64.96
	228.71	194.94	168.10	171.59	166.36	205.00
	25.05	21.36	18.35	18.56	17.97	22.12
Key metrics
	387.65	311.58	303.42	320.50	307.79	340.76
	13.60%	12.10%	12.70%	12.70%	11.30%	13.70%
	8.02%	7.60%	7.00%	6.80%	6.10%	8.20%
	—	12.90%	14.30%	—	—	—
	15.12%	7.50%	-5.60%	-6.90%	9.10%	—
	14.94%	16.00%	-2.00%	3.10%	-18.80%	—
	—	80.22	67.42	—	—	—
	—	1.30	1.45	—	—	—
	—	0.37	0.45	—	—	—
	—	567.56	607.66	—	—	—
	—	119.9	123.6	—	—	—
Balance sheet
	—	2,815	2,575	—	—	—
	—	1,468	1,338	—	—	—
	—	7.27	4.58	—	—	—
	—	829.87	751.18	—	—	—
	—	490.78	472.93	—	—	—
	—	122.14	80.88	—	—	—
	—	1,068	856.25	—	—	—
	—	477.88	416.14	—	—	—
	—	922.25	836.97	—	—	—
	—	574.83	612.24	—	—	—
	—	317.96	328.24	—	—	—
	—	256.87	284.00	—	—	—
	—	1,549	1,369	—	—	—
Cash flow
	—	253.54	244.58	—	—	—
	—	-173.41	-164.63	—	—	—
	—	-77.44	-82.12	—	—	—
	—	173.32	177.16	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	706.28	627.45	631.68	528.80	578.95	520.96	622.96	514.54	543.09	492.96	559.53	538.21
	2.65	0.20	0.83	1.22	0.15	0.38	1.71	11.37	0.38	0.11	1.11	1.68
	708.93	627.65	632.51	530.02	579.10	521.34	624.67	525.91	543.47	493.07	560.64	539.89
	632.20	557.71	573.95	508.31	523.32	476.09	554.00	473.88	502.58	457.91	510.90	497.02
	448.58	434.56	399.29	307.25	361.49	333.81	351.48	354.24	327.01	325.49	345.65	329.93
	12.22	12.45	12.12	12.34	9.84	11.21	13.49	9.49	11.94	9.42	10.91	5.64
	26.83	26.34	23.21	25.03	24.74	23.29	23.40	21.04	20.14	20.67	19.94	20.24
	7.81	6.95	6.59	6.95	6.01	6.82	7.48	7.57	7.17	7.46	8.09	6.75
	15.71	15.21	14.95	14.87	13.55	12.27	12.21	12.02	11.86	11.71	12.34	11.80
	128.48	119.86	123.72	111.69	112.67	101.34	104.85	102.12	100.86	93.25	99.47	94.49
	76.73	69.94	58.56	21.71	55.78	45.25	70.67	52.03	40.89	35.16	49.74	42.87
	0.00	-2.09	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	76.73	67.85	58.56	21.71	55.78	45.25	70.67	52.03	40.89	35.16	49.74	42.87
	19.05	17.00	13.60	12.13	14.00	-3.39	9.19	13.50	10.50	8.25	13.60	11.25
	57.68	50.85	44.96	33.84	41.78	48.64	61.48	38.53	30.39	26.91	36.14	31.62
	6.32	5.57	4.93	3.71	4.58	5.33	6.74	4.22	3.33	2.93	3.93	3.44
Key metrics
	100.25	90.01	80.10	43.53	75.34	64.34	90.36	71.62	59.92	54.33	70.17	61.42
	14.20%	14.30%	12.70%	8.20%	13.00%	12.40%	14.50%	13.90%	11.00%	11.00%	12.50%	11.40%
	8.20%	8.10%	7.10%	6.40%	7.20%	9.30%	9.90%	7.50%	5.60%	5.50%	6.50%	5.90%
	4.80%	—	3.90%	—	3.80%	—	5.00%	—	—	—	—	—
	22.00%	20.40%	1.40%	2.80%	6.60%	5.70%	11.30%	-4.40%	—	—	—	—
	38.10%	4.50%	-26.90%	-12.20%	37.50%	80.80%	70.10%	21.90%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	2,494	2,260	2,174	2,267	2,498	2,251
	4.90	2.59	13.58	4.18	2.23	4.77
	2,499	2,263	2,187	2,271	2,500	2,256
	2,272	2,082	1,988	2,079	2,295	2,000
	1,590	1,402	1,358	1,467	1,702	1,525
	49.13	45.51	44.34	35.86	47.01	58.31
	101.41	96.27	85.25	80.98	74.99	69.32
	28.30	26.38	29.68	30.16	32.53	20.06
	60.74	55.64	47.79	47.67	47.29	47.39
	483.75	449.40	401.08	390.60	397.85	358.74
	226.94	181.31	198.75	192.48	204.81	255.50
	-2.09	0.00	0.00	—	—	—
	224.85	181.31	198.75	192.48	204.81	255.50
	61.78	12.09	41.44	50.60	52.00	60.50
	187.33	169.22	157.31	141.88	152.81	195.00
	20.53	18.54	17.18	15.35	16.50	21.04
Key metrics
	313.89	263.33	276.22	270.31	284.63	322.95
	12.58%	11.60%	12.70%	11.90%	11.40%	14.30%
	7.51%	7.50%	7.20%	6.30%	6.10%	8.70%
	—	12.40%	14.60%	—	—	—
	11.48%	4.00%	-4.10%	-9.20%	11.00%	—
	-1.63%	7.60%	10.90%	-7.20%	-21.60%	—
	—	151.75	82.79	—	—	—
	—	1.50	1.40	—	—	—
	—	0.30	0.41	—	—	—
	—	416.40	510.64	—	—	—
	—	117.1	123.5	—	—	—
Balance sheet
	—	2,382	2,273	—	—	—
	—	1,213	1,181	—	—	—
	—	3.57	3.28	—	—	—
	—	732.41	701.72	—	—	—
	—	405.35	407.23	—	—	—
	—	54.68	40.37	—	—	—
	—	970.31	759.57	—	—	—
	—	413.31	373.11	—	—	—
	—	712.63	705.78	—	—	—
	—	419.97	513.92	—	—	—
	—	238.27	275.97	—	—	—
	—	181.70	237.95	—	—	—
	—	1,405	1,251	—	—	—
Cash flow
	—	254.14	220.08	—	—	—
	—	-127.58	-134.92	—	—	—
	—	-126.27	-84.60	—	—	—
	—	102.39	137.29	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: -3.28%
Sales CAGR 5Y: —
Profit CAGR 3Y: +3.46%
Profit CAGR 5Y: —
Sales YoY (TTM): +11.48%
Profit YoY (TTM): -1.63%

Consolidated

Sales CAGR 3Y: -1.89%
Sales CAGR 5Y: —
Profit CAGR 3Y: +5.43%
Profit CAGR 5Y: —
Sales YoY (TTM): +15.12%
Profit YoY (TTM): +14.94%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 54.06%

Quarter	September 2026	June 2026
Promoter %	54.06%	54.42%

Holder	Type	Holding	Previous	Change
PRAKASH MORESHWAR PATIL	Promoter	9.62%	9.62%	0.00%
DSP SMALL CAP FUND	Public	7.93%	7.93%	0.00%
HARSHIT MANILAL SAVLA	Promoter	4.73%	4.73%	0.00%
RASHESH CHANDRAKANT GOGRI	Promoter Group	4.64%	4.64%	0.00%
PRITI PRAKASH PATIL	Promoter Group	4.40%	4.40%	0.00%
SEEMA HARSHIT SAVLA	Promoter Group	3.83%	3.83%	0.00%
GOGRI FINSERV PVT. LTD.	Promoter Group	3.80%	3.80%	0.00%
HETAL GOGRI GALA	Promoter Group	3.05%	3.05%	0.00%
HARIT PRAGJI SHAH	Public	2.67%	2.67%	0.00%
ANUSHAKTI ENTERPRISE PRIVATE LIMITED	Promoter Group	2.62%	2.62%	0.00%
ALCHEMIE FINSERV PVT. LTD.	Promoter Group	2.21%	2.21%	0.00%
ICICI PRUDENTIAL HEALTHCARE FUND	Public	2.03%	—	—
CHANDRAKANT VALLABHAJI GOGRI	Promoter	1.87%	1.87%	0.00%
JAYSHREE HARIT SHAH	Public	1.78%	1.78%	0.00%
JAYA CHANDRAKANT GOGRI	Promoter Group	1.71%	1.71%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Aarti Drugs Limited	4,148	454.45	18.14	12.90%	+15.12% TTM	+14.94% TTM	-9.74%

Filings & corporate actions

Recent announcements

Audio recording for conference call for Analyst and Investors4 Nov 2026 · Company Update / Analyst / Investor Meet
Investor Presentation for Q2 FY273 Nov 2026 · Company Update / Investor Presentation
Press release on Financial results for Quarter and Half year ended September 20263 Nov 2026 · Company Update / Press Release / Media Release
Financial Results for the quarter and half year ended September 30, 20263 Nov 2026 · Board Meeting / Outcome of Board Meeting
Financial Results for the quarter and half year ended September 30, 20263 Nov 2026 · Result / Financial Results
Q2 H1 FY27 Earning Conference Call Intimation28 Oct 2026 · Company Update / Analyst / Investor Meet
Aarti Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Audited Financial Results for the ....27 Oct 2026 · Board Meeting / Board Meeting
Intimation under Regulation 30 of SEBI LODR, 2015 - Crisil ESG Rating8 Oct 2026 · Company Update / General
Certificate under Reg. 74(5) of SEBI (DP) Regulation, 20187 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Details of Authorized Persons under Regulation 30(5) of the SEBI LODR Regulations, 20151 Oct 2026 · Company Update / General
Change in Directorate/ Management30 Sep 2026 · Company Update / Change in Management
Closure of Trading Window29 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Change in Directors/ Management26 Sep 2026 · Company Update / Change in Directorate
Scrutinizer''s Report and Voting Results of 41st AGM26 Sep 2026 · AGM/EGM / AGM
Presentation made to the shareholders at 41st Annual General Meeting26 Sep 2026 · Company Update / Investor Presentation
Proceedings of 41st Annual General Meeting26 Sep 2026 · AGM/EGM / AGM
Newspaper Publication3 Sep 2026 · Company Update / Newspaper Publication
Please find attached BRSR for FY 2025-262 Sep 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Please find attached Notice of 41st Annual General Meeting of the Company2 Sep 2026 · AGM/EGM / AGM
Please find attached Annual Report for FY 2025-262 Sep 2026 · Others / Reg. 34 (1) Annual Report
Newspaper Publication1 Sep 2026 · Company Update / Newspaper Publication
approval of Aarti Drugs Limited Performance Stock Option Plan 202627 Aug 2026 · Board Meeting / Outcome of Board Meeting
Closure of Trading Window24 Aug 2026 · Insider Trading / SAST / Closure of Trading Window
Aarti Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/08/2026 ,inter alia, to consider and approve 'Aarti Drugs Limited - Performance ....24 Aug 2026 · Board Meeting / Board Meeting
Intimation of Analyst/ Institutional Meet14 Aug 2026 · Company Update / Analyst / Investor Meet
Disclosure under Regulation 30 of SEBI Listing Regulations10 Aug 2026 · Company Update / General
Q1FY27 Earning call transcript7 Aug 2026 · Company Update / Earnings Call Transcript
Intimation of Analyst /Institutional Investors Meeting4 Aug 2026 · Company Update / Analyst / Investor Meet
Q1FY27 Earning Conference call recording3 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication on Financial results3 Aug 2026 · Company Update / Newspaper Publication
Q1FY27 Investor Presentation1 Aug 2026 · Company Update / Investor Presentation
Press Release on Q1FY27 Business and Financial Performance1 Aug 2026 · Company Update / Press Release / Media Release
Revocation of closure order by GPCB related to plant located at Sayakha1 Aug 2026 · Company Update / General
Aarti Drugs Limited Announces Leadership Transition to Strengthen Governance and Ensure Long-term Strategic Growth31 Jul 2026 · Company Update / Press Release / Media Release
Change in Directorate31 Jul 2026 · Company Update / Change in Directorate
Financial Results for the quarter ended June 30, 202631 Jul 2026 · Board Meeting / Outcome of Board Meeting
Financial Results for the quarter ended June 30, 202631 Jul 2026 · Result / Financial Results
Q1 Earning Conference Call29 Jul 2026 · Company Update / Analyst / Investor Meet
Aarti Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve Financial results for the quarter ....24 Jul 2026 · Board Meeting / Board Meeting
Closure Directions by GPCB18 Jul 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Interim Dividend - Rs. - 2.0000	9 Feb 2026	9 Feb 2026	—
Interim Dividend - Rs. - 1.0000	4 Feb 2025	4 Feb 2025	—
Buy Back of Shares	5 Sep 2024	5 Sep 2024	—

Board meetings

3 Nov 2026 Board Meeting - Financial Results
31 Jul 2026 Board Meeting - Financial Results